Full length articleCo-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma

Add time:09/01/2019    Source:sciencedirect.com

Effective systemic therapy is highly desired for the treatment of hepatocellular carcinoma (HCC). In this study, a combination of nanoparticles of poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol)/combretastatin A4 sodium salt (CA4-NPs) plus sorafenib is developed for the cooperative systemic treatment of HCC. The CA4-NPs leads to the disruption of established tumor blood vessels and extensive tumor necrosis, however, inducing increased expression of VEGF-A and angiogenesis. Sorafenib reduces the VEGF-A induced angiogenesis and further inhibits tumor proliferation, cooperating with the CA4-NPs. A significant decrease in tumor volume and prolonged survival time are observed in the combination group of CA4-NPs plus sorafenib compared with CA4-NPs or sorafenib monotherapy in subcutaneous and orthotopic H22 hepatic tumor models. Seventy-one percent of the mice are alive without residual tumor at 96 days post tumor inoculation for the subcutaneous models treated with CA4-NPs 30 or 35 mg·kg−1 plus sorafenib 30 mg·kg−1. Our findings suggest that co-administration of sorafenib and CA4-NPs possesses significant antitumor efficacy for HCC treatment.

We also recommend Trading Suppliers and Manufacturers of Combretastatin A-3 (cas 111394-45-7). Pls Click Website Link as below: cas 111394-45-7 suppliers

Prev:Review articleDevelopment of combretastatins as potent tubulin polymerization inhibitors
Next:Review articleCombretastatins: In vitro structure-activity relationship, mode of action and current clinical status)